Vyome Holdings Inc. (HIND) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Vyome Holdings Inc. (HIND) trades at $2.28 with AI Score 17/100 (Grade F). Vyome Holdings Inc. is a clinical-stage healthcare company focused on developing therapeutic products for immuno-inflammatory and rare diseases. Market cap: $16.0M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for HIND: HIND does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HIND against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
HIND: 3/3 scored disciplines lean bearish. Dominant signal: Valuation weak.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Vyome Holdings Inc. (HIND) Healthcare & Pipeline Overview
Vyome Holdings Inc., a clinical-stage biotechnology company, focuses on developing therapeutics for immuno-inflammatory and rare diseases. With a presence in the United States and global markets, Vyome aims to address unmet medical needs through innovative product development and strategic market access.
What Is the Investment Thesis for HIND?
Vyome Holdings Inc. presents a high-risk, high-reward investment opportunity characteristic of clinical-stage biotechnology companies. The company's focus on immuno-inflammatory and rare diseases offers potential for significant growth if its therapeutic candidates achieve clinical success and regulatory approval. However, the company's negative profit margin of -452.4% highlights its reliance on external funding and the inherent risks associated with drug development. Key catalysts include upcoming clinical trial results and potential partnerships. Investors should carefully consider the company's financial position, the competitive landscape, and the regulatory hurdles involved in bringing new therapies to market. The company's beta of 1.42 suggests higher volatility compared to the broader market.
Based on FMP financials and quantitative analysis
HIND Key Highlights
Market capitalization of $16.0M reflects its small-cap status and potential for growth.
- Negative profit margin of -452.4% indicates that the company is currently operating at a loss, typical for clinical-stage biotech companies.
- Gross margin of 54.3% suggests strong potential profitability if products reach commercialization.
- Beta of 1.42 indicates higher volatility compared to the market, which is common for biotech stocks.
- Focus on immuno-inflammatory and rare diseases positions the company in a high-need therapeutic area.
Who Are HIND's Competitors?
HIND is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HIND's Key Strengths?
Focus on high-need therapeutic areas (immuno-inflammatory and rare diseases).
- Proprietary drug development platform.
- Experienced management team.
- Potential for breakthrough therapies.
What Are HIND's Weaknesses?
Limited financial resources.
- Reliance on successful clinical trial outcomes.
- High cash burn rate.
- Small number of employees.
What Could Drive HIND Stock Higher?
Results from ongoing clinical trials for lead therapeutic candidates.
- Potential partnerships or collaborations with larger pharmaceutical companies.
- Regulatory submissions for marketing approval of its products.
- Advancements in research and development efforts.
- Expansion of its product pipeline.
What Are the Key Risks for HIND?
Financial-distress signal — its Altman Z-Score of -11.80 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for its therapeutic products.
- Competition from other companies developing similar therapies.
- Patent challenges and intellectual property disputes.
- High cash burn rate and need for additional financing.
- Uncertainty in clinical trial outcomes.
What Are the Growth Opportunities for HIND?
- Expansion into New Therapeutic Areas: Vyome can leverage its expertise in immuno-inflammatory diseases to expand into adjacent therapeutic areas with unmet medical needs. This could involve developing therapies for autoimmune disorders or other chronic inflammatory conditions, thereby broadening its market reach and diversifying its product pipeline. The market for autoimmune disease therapeutics is projected to reach $150 billion by 2028, offering significant growth potential.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions can provide Vyome with access to additional funding, resources, and expertise. Collaborations can also accelerate the development and commercialization of its therapeutic candidates, enhancing its competitive position in the market. These partnerships could be established within the next 1-2 years.
- Successful Clinical Trial Outcomes: Positive results from ongoing and future clinical trials are crucial for driving growth and increasing investor confidence. Successful clinical trials can validate the efficacy and safety of Vyome's therapeutic candidates, leading to regulatory approvals and market access. The timeline for these outcomes depends on the specific clinical trial phases, typically spanning 2-5 years.
- Geographic Expansion: Expanding its operations beyond the United States to other global markets can unlock new revenue streams and increase its market share. This could involve establishing partnerships with local distributors or setting up its own commercial infrastructure in key regions. The global market for rare disease therapeutics is expected to grow significantly in the coming years, presenting a substantial opportunity.
- Advancements in Drug Delivery Technologies: Investing in and utilizing advanced drug delivery technologies can improve the efficacy and patient compliance of its therapeutic products. This could involve developing novel formulations or delivery systems that enhance drug absorption, reduce side effects, and improve overall treatment outcomes. These advancements could be integrated into its product development pipeline within the next 3-5 years.
What Are HIND's Competitive Advantages?
- Proprietary drug formulations and delivery technologies.
- Patent protection for its therapeutic products.
- Expertise in developing therapies for immuno-inflammatory and rare diseases.
- Established relationships with key opinion leaders and medical professionals.
What Does HIND Do?
Vyome Holdings Inc., established in 2017 and headquartered in Princeton, New Jersey, is a clinical-stage healthcare company dedicated to the development of therapeutic products targeting immuno-inflammatory and rare diseases. The company's mission is centered around addressing unmet medical needs through innovative research and development. Vyome focuses on identifying and developing novel therapies that can provide significant clinical benefits to patients suffering from these conditions. Vyome operates primarily in the United States and aims to expand its reach to global markets through strategic partnerships and collaborations. The company's pipeline includes various therapeutic candidates designed to modulate the immune system and target specific pathways involved in inflammatory and rare diseases. By leveraging its scientific expertise and clinical development capabilities, Vyome seeks to bring transformative treatments to patients with limited therapeutic options, thereby improving their quality of life and overall health outcomes. Vyome's commitment to innovation and patient-centricity drives its efforts to advance the field of immuno-inflammatory and rare disease therapeutics.
What Products and Services Does HIND Offer?
- Develops therapeutic products targeting immuno-inflammatory diseases.
- Focuses on treatments for rare diseases.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks regulatory approvals from agencies like the FDA.
- Aims to commercialize its products in the United States and global markets.
- Engages in research and development to discover new therapeutic targets.
- Collaborates with other companies and research institutions.
How Does HIND Make Money?
- Develops and patents novel therapeutic products.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through milestone payments and royalties on product sales.
- Raises capital through equity financing and potential debt offerings.
What Industry Does HIND Operate In?
Vyome Holdings Inc. operates within the biotechnology sector, which is characterized by high innovation, intense competition, and significant regulatory oversight. The market for immuno-inflammatory and rare disease therapeutics is growing, driven by increasing prevalence of these conditions and advancements in medical technology. Companies in this sector face challenges such as lengthy and costly clinical trials, regulatory hurdles, and the need for substantial capital investment. Vyome competes with other biotechnology and pharmaceutical companies developing therapies for similar indications, requiring a strong focus on differentiation and clinical efficacy.
Who Are HIND's Key Customers?
- Patients suffering from immuno-inflammatory diseases.
- Patients with rare diseases.
- Healthcare providers who prescribe and administer the company's products.
- Pharmaceutical companies that may license or acquire the company's products.
How Vyome Holdings Inc. Is Valued
Vyome Holdings Inc. carries a market capitalization of $16.0M, placing it in the micro-cap category. Relative to its peer group, HIND's quantitative score of 17/100 is below the peer average of 76/100.
Company Profile
Vyome Holdings Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Venkateswarlu Nelabhotla. HIND has traded publicly since 2016.
Key Financial Metrics
Its free cash flow yield is -25.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.27 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -104.1%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Vyome Holdings Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -11.80 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Vyome Holdings Inc. revenue of about $300K for fiscal 2026, with EPS near $-0.70.
HIND Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that key stakeholders believe in a positive turnaround.
- Community sentiment has shifted positively, with discussions highlighting the innovative drug development pipeline as a major growth driver.
- Analysts have noted increased interest in Vyome's unique therapeutic approaches, which could position the company favorably in niche markets.
- Recent partnerships and collaborations have sparked optimism about potential revenue growth and market expansion.
Bear Case
- Some investors express concerns over the company's ability to deliver on its ambitious timelines, leading to skepticism in the community.
- Market perception remains cautious due to the competitive landscape in the biotech sector, where many companies face similar challenges.
- Recent quarterly results have raised questions about operational efficiency, causing some bearish sentiment among traders.
- Negative sentiment has stemmed from regulatory hurdles that could delay product launches, impacting investor confidence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
HIND Latest News
No recent news available for HIND.
HIND Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HIND.
Price Targets
Wall Street price target analysis for HIND.
HIND MoonshotScore
What does this score mean?
The MoonshotScore rates HIND 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Venkateswarlu Nelabhotla
CEO
Venkateswarlu Nelabhotla serves as the CEO of Vyome Holdings Inc. His background includes extensive experience in the pharmaceutical and biotechnology industries. He has held various leadership positions in companies focused on drug development and commercialization. Nelabhotla's expertise spans across strategic planning, clinical operations, and business development. He is responsible for guiding Vyome's overall strategy and driving the company's growth initiatives. His leadership is crucial in navigating the complexities of the healthcare sector and ensuring the company's success.
Track Record: Under Venkateswarlu Nelabhotla's leadership, Vyome Holdings Inc. has focused on advancing its pipeline of therapeutic candidates for immuno-inflammatory and rare diseases. Key milestones include initiating and progressing clinical trials, securing partnerships, and raising capital to support its research and development efforts. His strategic decisions have been instrumental in shaping the company's direction and positioning it for future growth.
What Investors Ask About Vyome Holdings Inc. (HIND) — Healthcare
What does the AI Score mean for HIND?
HIND holds an AI Score of 17/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Vyome Holdings Inc. is a clinical-stage healthcare company focused on developing therapeutic products for immuno-inflammatory and rare diseases. Founded in 2017, the company targets markets in …
What does Vyome Holdings, Inc. do?
Vyome Holdings Inc. is a clinical-stage healthcare company focused on developing and commercializing innovative therapeutic products for immuno-inflammatory and rare diseases. The company's primary focus is on identifying and developing novel therapies that address unmet medical needs in these therapeutic areas.
What do analysts say about HIND stock?
As of May 10, 2026, analyst coverage on Vyome Holdings Inc. (HIND) is limited due to its small market capitalization and clinical-stage status. Key valuation metrics are difficult to assess given the company's negative profit margin and reliance on future product approvals.
What are the main risks for HIND?
Vyome Holdings Inc. faces several key risks inherent to its business model and industry. These include the risk of failure to obtain regulatory approvals for its therapeutic products, competition from other companies developing similar therapies, and potential patent challenges.
What are the key factors to evaluate for HIND?
Vyome Holdings Inc. (HIND) holds an AI score of 17/100 (low). presents a high-risk, high-reward investment opportunity characteristic of clinical-stage biotechnology companies. Not financial advice.
How frequently does HIND data refresh on this page?
HIND's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HIND's recent stock price performance?
Vyome Holdings Inc. (HIND) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on high-need therapeutic areas (immuno-inflammatory and rare diseases). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HIND overvalued or undervalued right now?
Vyome Holdings Inc. (HIND) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research HIND before investing?
Before investing in Vyome Holdings Inc. (HIND), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is as of the last reported period.
- This is not investment advice. Conduct thorough due diligence before making any investment decisions.